Avalo Therapeutics (NASDAQ:AVTX) used a presentation at its 46th Annual Healthcare Conference appearance to outline its strategy for AVTX-009, a high-affinity human monoclonal antibody designed to ...
These results are particularly meaningful, as the landscape of MSS colorectal cancer treatment has seen little advancement leaving a significant gap in effective therapies for patients. “MSS ...
The company expects to present updated results from the Phase 2 NSCLC trial, including Duration of Response (DOR) and Progression-free Survival (PFS) data in both the recurrent (83 patients) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results